Lantern Pharma (NASDAQ:LTRN) Stock Price Down 4.9% – Here’s Why

17 Jun 2026, 22:27 by Scott Moore · The Cerbat Gem

Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report)’s share price traded down 4.9% on Monday . The stock traded as low as $3.62 and last traded at $3.69. 197,530 shares changed hands during mid-day trading, a decline of 16% from the average session volume of 235,778 shares. The stock had previously closed at $3.88.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Lantern Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings cut shares of Lantern Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Check Out Our Latest Analysis on LTRN

Lantern Pharma Trading Down 0.5%

The firm’s fifty day moving average price is $2.90 and its 200 day moving average price is $2.92. The stock has a market capitalization of $49.64 million, a price-to-earnings ratio of -2.68 and a beta of 2.33.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06.

Insider Activity at Lantern Pharma

In related news, Director Lee Troy Schalop acquired 48,544 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the acquisition, the director owned 48,544 shares in the company, valued at $100,000.64. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director D Jeffrey Keyser acquired 48,544 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was bought at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the completion of the acquisition, the director owned 94,303 shares in the company, valued at approximately $194,264.18. The trade was a 106.09% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Lantern Pharma

Several large investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new stake in Lantern Pharma during the 3rd quarter worth approximately $170,000. Vanguard Group Inc. lifted its holdings in Lantern Pharma by 5.6% during the 3rd quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after buying an additional 20,321 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Lantern Pharma by 10.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock worth $335,000 after buying an additional 10,300 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Lantern Pharma by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock worth $293,000 after buying an additional 4,661 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Lantern Pharma during the 3rd quarter worth approximately $70,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

About Lantern Pharma

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.